Vitamin B12 (cobalamin) deficiency is a clinically important nutritional and hematologic condition arising when total body stores are insufficient to meet metabolic demands. B12 is required as an essential cofactor for two major biochemical pathways: (1) methionine synthase, which converts homocysteine to methionine and supports methylation reactions necessary for DNA synthesis and normal cellular function; and (2) methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA, enabling normal fatty acid metabolism. When B12 is lacking, disrupted methylation and abnormal fatty acid incorporation impair rapidly dividing tissues and contribute to neurologic dysfunction. This dual impact explains why deficiency can present with both hematologic abnormalities (often macrocytosis and megaloblastic anemia) and neurologic symptoms (including paresthesias and gait instability).
Hematologic manifestations commonly include megaloblastic anemia characterized by impaired DNA synthesis leading to ineffective erythropoiesis. Patients may report fatigue, weakness, dyspnea on exertion, palpitations, and pallor. Laboratory findings frequently show elevated mean corpuscular volume, hypersegmented neutrophils, and low or borderline hemoglobin depending on severity. However, absence of anemia does not exclude clinically meaningful B12 deficiency, and neurologic symptoms can occur independently or in advance of hematologic changes. Neurologic features result from myelin dysfunction and axonal injury pathways linked to altered methylation and accumulation of potentially neurotoxic metabolites. Common neurologic complaints include numbness or tingling in hands and feet (peripheral neuropathy), balance impairment, cognitive difficulties, mood changes, and in severe cases subacute combined degeneration affecting spinal cord tracts.
Because early symptoms can overlap with other conditions (e.g., folate deficiency, diabetes-related neuropathy, thyroid disease, alcohol-related liver disease), diagnostic evaluation should be systematic. First-line testing typically includes serum vitamin B12, complete blood count, and peripheral smear. If initial B12 levels are borderline or clinical suspicion remains high, functional biomarkers improve diagnostic accuracy: serum methylmalonic acid (MMA) and homocysteine tend to rise in true B12 deficiency (MMA is especially specific), while folate deficiency generally increases homocysteine without markedly elevating MMA. Additional workup may include reticulocyte count, liver function tests, and evaluation of anemia patterns. In certain circumstances, evaluation for malabsorption causes is essential.
The most common etiologies involve impaired absorption. Pernicious anemia, an autoimmune condition characterized by antibodies against intrinsic factor and/or gastric parietal cells, prevents B12 uptake in the terminal ileum. Other gastrointestinal causes include atrophic gastritis, gastric or ileal surgery, inflammatory bowel disease affecting the terminal ileum, and pancreatic insufficiency or malabsorptive disorders such as celiac disease. Dietary insufficiency can occur in individuals with low intake of animal-derived foods (e.g., strict vegan diets) or in older adults with reduced dietary variety and stomach acid changes that impair absorption. Medication-related causes are also clinically relevant: metformin can reduce intestinal B12 absorption, and chronic proton pump inhibitor use may decrease gastric acidity needed for B12 release from food proteins.
Clinical management prioritizes prompt replacement to prevent irreversible neurologic injury. Route selection depends on severity, absorption capability, and neurologic involvement. For malabsorption states or severe deficiency with neurologic symptoms, parenteral therapy (intramuscular or deep subcutaneous B12) is often preferred because it bypasses gastrointestinal absorption. For patients with dietary deficiency and intact absorption, high-dose oral supplementation may be effective; large oral doses can overcome absorption limitations via passive diffusion. Folate should be assessed and corrected when appropriate, because folate replacement alone can improve anemia while allowing neurologic deterioration from untreated B12 deficiency to continue.
Monitoring includes reassessment of symptoms and repeat laboratory tests. Hematologic improvement typically occurs within weeks with rising reticulocytes and gradual normalization of hemoglobin and indices. Neurologic recovery is variable and may be incomplete if treatment is delayed; earlier intervention generally yields better outcomes. Persistent symptoms warrant evaluation for alternative etiologies or coexisting deficiencies.
Prevention and risk mitigation focus on identifying high-risk groups: older adults, patients on long-term acid-suppressing therapy, individuals taking metformin, those with known malabsorptive disorders, and people following restrictive diets. Evidence-based supplementation and targeted screening for B12 deficiency in appropriate clinical contexts can reduce morbidity. If symptoms suggest deficiency—especially combined neurologic and hematologic features—timely testing and treatment are essential.
Source: WebMD
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
